Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Safety and Efficacy of Long-term Somatropin Treatment in Adults
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 752
- Registration Number
- NCT01543880
Safety and Efficacy of Long-term Somatropin Treatment in Children
Completed
- Conditions
- Growth Hormone Deficiency in ChildrenSmall for Gestational AgeTurner SyndromeGrowth Hormone DisorderFoetal Growth ProblemGenetic DisorderGrowth DisorderIdiopathic Short Stature
- Interventions
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5442
- Registration Number
- NCT01543867
Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: insulin detemirDrug: insulin NPH
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT01542450
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment Satisfaction
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT01542476
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1889
- Registration Number
- NCT01542424
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Skopje, Macedonia, The Former Yugoslav Republic of
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
Completed
- Conditions
- Diabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT01542489
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4464
- Registration Number
- NCT01542463
Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 298
- Registration Number
- NCT01542060
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 135
- Registration Number
- NCT01541215
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Special Survey for Patients With Type 1 or Type 2 Diabetes
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1582
- Registration Number
- NCT01538589
© Copyright 2025. All Rights Reserved by MedPath